PDCD1 and neoplasm: The clinical efficacy of such a therapeutic strategy could be further enhanced by the selection of highly reactive T cells for adoptive therapy via pretreatment with ICIs such as anti-PD-1 [19] to reduce the tumour burden and, thus, increase the presumed benefit of TILs treatment [23].